Join Arcutis Biotherapeutics for a virtual Key Opinion Leader (KOL) event featuring a leading dermatology and immune-mediated skin disease expert to discuss the unmet need and current treatment landscape for patients with mild to moderate atopic dermatitis (AD).

The event will highlight the differentiating features of and commercialization plans for ZORYVE^® (roflumilast) cream 0.15%, which recently received FDA approval for the treatment of AD in adults and children aged 6 years and older. For more information, click here.